beta

APHB

AmpliPhi Biosciences Corporation

Aphb

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

03-24-2019 03-24-2019 03-24-2019 03-24-2019 03-24-2019 03-24-2019 03-24-2019 03-24-2019 03-24-2019 03-24-2019 11-08-2018 08-09-2018 05-15-2018 after market close 03-14-2018 11-14-2017 after market close 08-14-2017 after market close 05-15-2017
Actual EPS -0.15 -0.15 -0.15 -0.15 -0.15 -0.15 -0.15 -0.15 -0.15 -0.15 -0.1 -0.19 -0.24 -0.25 -0.09 -0.78 -1.94
Consensus EPS -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.12 -0.2 -0.19 -0.36 -0.46 -0.8 -8.2
Estimated EPS -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.08 -0.12 -0.2 -0.19 -0.36 -0.46 -0.8 -8.2
Number of Estimates 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1
EPS Surprise -$0.07 -$0.07 -$0.07 -$0.07 -$0.07 -$0.07 -$0.07 -$0.07 -$0.07 -$0.07 $0.02 $0.01 -$0.05 $0.11 $0.37 $0.02 $6.26

Stats

Summary

Ampliphi Biosciences Corp is a biotechnology company engaged in the discovery, development and commercialization of novel phage therapeutics. The Company's pipeline is based on the use of bacteriophages.

Market Cap: 14.7 Million

Primary Exchange: NYSE American

Website: http://www.ampliphibio.com

Shares Outstanding: 13.5 Million

Float: 13 Million

Dividend: 0.0 (0.0%)

Beta: 3.189582

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 1.16 Million

Ethical Flags

Animal testing

Longest drawdown: 2168 trading days

From: 2013-07-24 To: 2019-04-22

Lowest Point:

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

via: PR Newswire at 2019-04-05 12:24:00:000

NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like … read more...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHB

via: PR Newswire at 2019-03-27 03:49:00:000

NEW YORK , March 27, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating the Board of Directors of AmpliPhi Biosciences… read more...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHB

via: PR Newswire at 2019-03-27 03:49:00:000

NEW YORK , March 27, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating the Board of Directors of AmpliPhi Biosciences… read more...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHB

via: PR Newswire at 2019-03-27 03:49:00:000

NEW YORK , March 27, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating the Board of Directors of AmpliPhi Biosciences… read more...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHB

via: PR Newswire at 2019-03-27 03:49:00:000

NEW YORK , March 27, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating the Board of Directors of AmpliPhi Biosciences… read more...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHB

via: PR Newswire at 2019-03-27 03:49:00:000

NEW YORK , March 27, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating the Board of Directors of AmpliPhi Biosciences… read more...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHB

via: PR Newswire at 2019-03-27 03:49:00:000

NEW YORK , March 27, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating the Board of Directors of AmpliPhi Biosciences… read more...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHB

via: PR Newswire at 2019-03-27 03:49:00:000

NEW YORK , March 27, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating the Board of Directors of AmpliPhi Biosciences… read more...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHB

via: PR Newswire at 2019-03-27 03:49:00:000

NEW YORK , March 27, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating the Board of Directors of AmpliPhi Biosciences… read more...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHB

via: PR Newswire at 2019-03-27 03:49:00:000

NEW YORK , March 27, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating the Board of Directors of AmpliPhi Biosciences… read more...

AmpliPhi Biosciences reports Q4 results

via: SeekingAlpha at 2019-03-25 05:27:52:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q4 GAAP EPS of -$0.15. More news on: AmpliPhi Biosciences Corporation, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences reports Q4 results

via: SeekingAlpha at 2019-03-25 05:27:52:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q4 GAAP EPS of -$0.15. More news on: AmpliPhi Biosciences Corporation, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights

via: Business Wire at 2019-03-25 05:01:00:000

Entered into a merger agreement with C3J Therapeutics that is expected to result in an NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics $10.0 million of new capital will be invested in combined company to be re-named Armata Pharmac… read more...

AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights

via: Business Wire at 2019-03-25 05:01:00:000

Entered into a merger agreement with C3J Therapeutics that is expected to result in an NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics $10.0 million of new capital will be invested in combined company to be re-named Armata Pharmac… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 19:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)

via: SeekingAlpha at 2019-01-14 14:07:04:000

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial O… read more...

AmpliPhi Bio up 45% premarket on merger with C3J Therapeutics

via: SeekingAlpha at 2019-01-04 09:17:52:000

Nano cap AmpliPhi Biosciences (NYSEMKT: APHB ) is up 45% premarket on robust volume on the heels of its announced merger with privately held C3J Therapeutics , a developer of targeted antimicrobials. More news on: AmpliPhi Biosciences Corp., Healthcare stocks news, Merger &a… read more...

AmpliPhi Bio up 45% premarket on merger with C3J Therapeutics

via: SeekingAlpha at 2019-01-04 09:17:52:000

Nano cap AmpliPhi Biosciences (NYSEMKT: APHB ) is up 45% premarket on robust volume on the heels of its announced merger with privately held C3J Therapeutics , a developer of targeted antimicrobials. More news on: AmpliPhi Biosciences Corp., Healthcare stocks news, Merger &a… read more...

AmpliPhi Bio up 45% premarket on merger with C3J Therapeutics

via: SeekingAlpha at 2019-01-04 09:17:52:000

Nano cap AmpliPhi Biosciences (NYSEMKT: APHB ) is up 45% premarket on robust volume on the heels of its announced merger with privately held C3J Therapeutics , a developer of targeted antimicrobials. More news on: AmpliPhi Biosciences Corp., Healthcare stocks news, Merger &a… read more...

AmpliPhi Bio up 45% premarket on merger with C3J Therapeutics

via: SeekingAlpha at 2019-01-04 09:17:52:000

Nano cap AmpliPhi Biosciences (NYSEMKT: APHB ) is up 45% premarket on robust volume on the heels of its announced merger with privately held C3J Therapeutics , a developer of targeted antimicrobials. More news on: AmpliPhi Biosciences Corp., Healthcare stocks news, Merger &a… read more...

AmpliPhi Bio up 45% premarket on merger with C3J Therapeutics

via: SeekingAlpha at 2019-01-04 09:17:52:000

Nano cap AmpliPhi Biosciences (NYSEMKT: APHB ) is up 45% premarket on robust volume on the heels of its announced merger with privately held C3J Therapeutics , a developer of targeted antimicrobials. More news on: AmpliPhi Biosciences Corp., Healthcare stocks news, Merger &a… read more...

AmpliPhi Bio up 45% premarket on merger with C3J Therapeutics

via: SeekingAlpha at 2019-01-04 09:17:52:000

Nano cap AmpliPhi Biosciences (NYSEMKT: APHB ) is up 45% premarket on robust volume on the heels of its announced merger with privately held C3J Therapeutics , a developer of targeted antimicrobials. More news on: AmpliPhi Biosciences Corp., Healthcare stocks news, Merger &a… read more...

AmpliPhi Bio up 45% premarket on merger with C3J Therapeutics

via: SeekingAlpha at 2019-01-04 09:17:52:000

Nano cap AmpliPhi Biosciences (NYSEMKT: APHB ) is up 45% premarket on robust volume on the heels of its announced merger with privately held C3J Therapeutics , a developer of targeted antimicrobials. More news on: AmpliPhi Biosciences Corp., Healthcare stocks news, Merger &a… read more...

AmpliPhi Bio up 45% premarket on merger with C3J Therapeutics

via: SeekingAlpha at 2019-01-04 09:17:52:000

Nano cap AmpliPhi Biosciences (NYSEMKT: APHB ) is up 45% premarket on robust volume on the heels of its announced merger with privately held C3J Therapeutics , a developer of targeted antimicrobials. More news on: AmpliPhi Biosciences Corp., Healthcare stocks news, Merger &a… read more...

AmpliPhi Bio up 45% premarket on merger with C3J Therapeutics

via: SeekingAlpha at 2019-01-04 09:17:52:000

Nano cap AmpliPhi Biosciences (NYSEMKT: APHB ) is up 45% premarket on robust volume on the heels of its announced merger with privately held C3J Therapeutics , a developer of targeted antimicrobials. More news on: AmpliPhi Biosciences Corp., Healthcare stocks news, Merger &a… read more...

AmpliPhi Bio up 45% premarket on merger with C3J Therapeutics

via: SeekingAlpha at 2019-01-04 09:17:52:000

Nano cap AmpliPhi Biosciences (NYSEMKT: APHB ) is up 45% premarket on robust volume on the heels of its announced merger with privately held C3J Therapeutics , a developer of targeted antimicrobials. More news on: AmpliPhi Biosciences Corp., Healthcare stocks news, Merger &a… read more...

AmpliPhi Bio up 45% premarket on merger with C3J Therapeutics

via: SeekingAlpha at 2019-01-04 09:17:52:000

Nano cap AmpliPhi Biosciences (NYSEMKT: APHB ) is up 45% premarket on robust volume on the heels of its announced merger with privately held C3J Therapeutics , a developer of targeted antimicrobials. More news on: AmpliPhi Biosciences Corp., Healthcare stocks news, Merger &a… read more...

AmpliPhi Biosciences and C3J Therapeutics Agree to Merge

via: Business Wire at 2019-01-04 08:00:00:000

Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhis extensive phage library and Phase 1/2-ready asset with C3Js expertise in synthetic phage and broad preclinical pipelin… read more...

AmpliPhi Biosciences and C3J Therapeutics Agree to Merge

via: Business Wire at 2019-01-04 08:00:00:000

Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhis extensive phage library and Phase 1/2-ready asset with C3Js expertise in synthetic phage and broad preclinical pipelin… read more...

AmpliPhi Biosciences and C3J Therapeutics Agree to Merge

via: Business Wire at 2019-01-04 08:00:00:000

Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhis extensive phage library and Phase 1/2-ready asset with C3Js expertise in synthetic phage and broad preclinical pipelin… read more...

AmpliPhi Biosciences and C3J Therapeutics Agree to Merge

via: Business Wire at 2019-01-04 08:00:00:000

Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhis extensive phage library and Phase 1/2-ready asset with C3Js expertise in synthetic phage and broad preclinical pipelin… read more...

AmpliPhi Biosciences and C3J Therapeutics Agree to Merge

via: Business Wire at 2019-01-04 08:00:00:000

Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhis extensive phage library and Phase 1/2-ready asset with C3Js expertise in synthetic phage and broad preclinical pipelin… read more...

AmpliPhi Biosciences and C3J Therapeutics Agree to Merge

via: Business Wire at 2019-01-04 08:00:00:000

Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhis extensive phage library and Phase 1/2-ready asset with C3Js expertise in synthetic phage and broad preclinical pipelin… read more...

AmpliPhi Biosciences and C3J Therapeutics Agree to Merge

via: Business Wire at 2019-01-04 08:00:00:000

Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhis extensive phage library and Phase 1/2-ready asset with C3Js expertise in synthetic phage and broad preclinical pipelin… read more...

AmpliPhi Biosciences and C3J Therapeutics Agree to Merge

via: Business Wire at 2019-01-04 08:00:00:000

Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhis extensive phage library and Phase 1/2-ready asset with C3Js expertise in synthetic phage and broad preclinical pipelin… read more...

AmpliPhi Biosciences and C3J Therapeutics Agree to Merge

via: Business Wire at 2019-01-04 08:00:00:000

Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhis extensive phage library and Phase 1/2-ready asset with C3Js expertise in synthetic phage and broad preclinical pipelin… read more...

AmpliPhi Biosciences and C3J Therapeutics Agree to Merge

via: Business Wire at 2019-01-04 08:00:00:000

Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhis extensive phage library and Phase 1/2-ready asset with C3Js expertise in synthetic phage and broad preclinical pipelin… read more...

AmpliPhi Biosciences and C3J Therapeutics Agree to Merge

via: Business Wire at 2019-01-04 08:00:00:000

Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhis extensive phage library and Phase 1/2-ready asset with C3Js expertise in synthetic phage and broad preclinical pipelin… read more...

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

via: SeekingAlpha at 2018-12-18 07:16:15:000

AmpliPhi Biosciences (NYSEMKT: APHB ) announces a 10-fold increase in yield from its manufacturing process, the result of enhanced manufacturing efficiencies for AB-SA01, the companys clinical stage lead drug product candidate. More news on: AmpliPhi Biosciences Corp., Healthcare… read more...

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

via: SeekingAlpha at 2018-12-18 07:16:15:000

AmpliPhi Biosciences (NYSEMKT: APHB ) announces a 10-fold increase in yield from its manufacturing process, the result of enhanced manufacturing efficiencies for AB-SA01, the companys clinical stage lead drug product candidate. More news on: AmpliPhi Biosciences Corp., Healthcare… read more...

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

via: SeekingAlpha at 2018-12-18 07:16:15:000

AmpliPhi Biosciences (NYSEMKT: APHB ) announces a 10-fold increase in yield from its manufacturing process, the result of enhanced manufacturing efficiencies for AB-SA01, the companys clinical stage lead drug product candidate. More news on: AmpliPhi Biosciences Corp., Healthcare… read more...

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

via: SeekingAlpha at 2018-12-18 07:16:15:000

AmpliPhi Biosciences (NYSEMKT: APHB ) announces a 10-fold increase in yield from its manufacturing process, the result of enhanced manufacturing efficiencies for AB-SA01, the companys clinical stage lead drug product candidate. More news on: AmpliPhi Biosciences Corp., Healthcare… read more...

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

via: SeekingAlpha at 2018-12-18 07:16:15:000

AmpliPhi Biosciences (NYSEMKT: APHB ) announces a 10-fold increase in yield from its manufacturing process, the result of enhanced manufacturing efficiencies for AB-SA01, the companys clinical stage lead drug product candidate. More news on: AmpliPhi Biosciences Corp., Healthcare… read more...

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

via: SeekingAlpha at 2018-12-18 07:16:15:000

AmpliPhi Biosciences (NYSEMKT: APHB ) announces a 10-fold increase in yield from its manufacturing process, the result of enhanced manufacturing efficiencies for AB-SA01, the companys clinical stage lead drug product candidate. More news on: AmpliPhi Biosciences Corp., Healthcare… read more...

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

via: SeekingAlpha at 2018-12-18 07:16:15:000

AmpliPhi Biosciences (NYSEMKT: APHB ) announces a 10-fold increase in yield from its manufacturing process, the result of enhanced manufacturing efficiencies for AB-SA01, the companys clinical stage lead drug product candidate. More news on: AmpliPhi Biosciences Corp., Healthcare… read more...

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

via: SeekingAlpha at 2018-12-18 07:16:15:000

AmpliPhi Biosciences (NYSEMKT: APHB ) announces a 10-fold increase in yield from its manufacturing process, the result of enhanced manufacturing efficiencies for AB-SA01, the companys clinical stage lead drug product candidate. More news on: AmpliPhi Biosciences Corp., Healthcare… read more...

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

via: SeekingAlpha at 2018-12-18 07:16:15:000

AmpliPhi Biosciences (NYSEMKT: APHB ) announces a 10-fold increase in yield from its manufacturing process, the result of enhanced manufacturing efficiencies for AB-SA01, the companys clinical stage lead drug product candidate. More news on: AmpliPhi Biosciences Corp., Healthcare… read more...

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

via: SeekingAlpha at 2018-12-18 07:16:15:000

AmpliPhi Biosciences (NYSEMKT: APHB ) announces a 10-fold increase in yield from its manufacturing process, the result of enhanced manufacturing efficiencies for AB-SA01, the companys clinical stage lead drug product candidate. More news on: AmpliPhi Biosciences Corp., Healthcare… read more...

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

via: SeekingAlpha at 2018-12-18 07:16:15:000

AmpliPhi Biosciences (NYSEMKT: APHB ) announces a 10-fold increase in yield from its manufacturing process, the result of enhanced manufacturing efficiencies for AB-SA01, the companys clinical stage lead drug product candidate. More news on: AmpliPhi Biosciences Corp., Healthcare… read more...

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

via: SeekingAlpha at 2018-12-18 07:16:15:000

AmpliPhi Biosciences (NYSEMKT: APHB ) announces a 10-fold increase in yield from its manufacturing process, the result of enhanced manufacturing efficiencies for AB-SA01, the companys clinical stage lead drug product candidate. More news on: AmpliPhi Biosciences Corp., Healthcare… read more...

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

via: SeekingAlpha at 2018-12-18 07:16:15:000

AmpliPhi Biosciences (NYSEMKT: APHB ) announces a 10-fold increase in yield from its manufacturing process, the result of enhanced manufacturing efficiencies for AB-SA01, the companys clinical stage lead drug product candidate. More news on: AmpliPhi Biosciences Corp., Healthcare… read more...

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

via: SeekingAlpha at 2018-12-18 07:16:15:000

AmpliPhi Biosciences (NYSEMKT: APHB ) announces a 10-fold increase in yield from its manufacturing process, the result of enhanced manufacturing efficiencies for AB-SA01, the companys clinical stage lead drug product candidate. More news on: AmpliPhi Biosciences Corp., Healthcare… read more...

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

via: SeekingAlpha at 2018-12-18 07:16:15:000

AmpliPhi Biosciences (NYSEMKT: APHB ) announces a 10-fold increase in yield from its manufacturing process, the result of enhanced manufacturing efficiencies for AB-SA01, the companys clinical stage lead drug product candidate. More news on: AmpliPhi Biosciences Corp., Healthcare… read more...

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

via: SeekingAlpha at 2018-12-18 07:16:15:000

AmpliPhi Biosciences (NYSEMKT: APHB ) announces a 10-fold increase in yield from its manufacturing process, the result of enhanced manufacturing efficiencies for AB-SA01, the companys clinical stage lead drug product candidate. More news on: AmpliPhi Biosciences Corp., Healthcare… read more...

AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01

via: SeekingAlpha at 2018-12-18 07:16:15:000

AmpliPhi Biosciences (NYSEMKT: APHB ) announces a 10-fold increase in yield from its manufacturing process, the result of enhanced manufacturing efficiencies for AB-SA01, the companys clinical stage lead drug product candidate. More news on: AmpliPhi Biosciences Corp., Healthcare… read more...

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

via: Business Wire at 2018-12-18 06:50:00:000

AmpliPhis wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology compan… read more...

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

via: Business Wire at 2018-12-18 06:50:00:000

AmpliPhis wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology compan… read more...

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

via: Business Wire at 2018-12-18 06:50:00:000

AmpliPhis wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology compan… read more...

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

via: Business Wire at 2018-12-18 06:50:00:000

AmpliPhis wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology compan… read more...

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

via: Business Wire at 2018-12-18 06:50:00:000

AmpliPhis wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology compan… read more...

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

via: Business Wire at 2018-12-18 06:50:00:000

AmpliPhis wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology compan… read more...

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

via: Business Wire at 2018-12-18 06:50:00:000

AmpliPhis wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology compan… read more...

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

via: Business Wire at 2018-12-18 06:50:00:000

AmpliPhis wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology compan… read more...

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

via: Business Wire at 2018-12-18 06:50:00:000

AmpliPhis wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology compan… read more...

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

via: Business Wire at 2018-12-18 06:50:00:000

AmpliPhis wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology compan… read more...

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

via: Business Wire at 2018-12-18 06:50:00:000

AmpliPhis wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology compan… read more...

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

via: Business Wire at 2018-12-18 06:50:00:000

AmpliPhis wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology compan… read more...

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

via: Business Wire at 2018-12-18 06:50:00:000

AmpliPhis wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology compan… read more...

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

via: Business Wire at 2018-12-18 06:50:00:000

AmpliPhis wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology compan… read more...

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

via: Business Wire at 2018-12-18 06:50:00:000

AmpliPhis wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology compan… read more...

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

via: Business Wire at 2018-12-18 06:50:00:000

AmpliPhis wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology compan… read more...

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

via: Business Wire at 2018-12-18 06:50:00:000

AmpliPhis wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology compan… read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences beats by $0.04

via: SeekingAlpha at 2018-11-08 16:53:11:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 GAAP EPS of -$0.10 beats by $0.04 . More news on: AmpliPhi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-11-08 16:10:00:000

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the companys expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% tre… read more...

AmpliPhi Biosciences Announces Closing of Public Offering

via: Business Wire at 2018-10-16 16:10:00:000

AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the closing of its previously anno… read more...

AmpliPhi Biosciences Announces Closing of Public Offering

via: Business Wire at 2018-10-16 16:10:00:000

AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the closing of its previously anno… read more...

AmpliPhi Biosciences Announces Closing of Public Offering

via: Business Wire at 2018-10-16 16:10:00:000

AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the closing of its previously anno… read more...

AmpliPhi Biosciences prices $6.6M equity offering; shares down 34% premarket

via: SeekingAlpha at 2018-10-12 06:18:33:000

AmpliPhi Biosciences (NYSEMKT: APHB ) prices its public offering of 16,537,500 shares of common stock and warrants to purchase up to 16,537,500 common shares and pre-funded warrants at a combined price of $0.40. More news on: AmpliPhi Biosciences Corp., Healthcare stocks news, Stocks on … read more...

AmpliPhi Biosciences prices $6.6M equity offering; shares down 34% premarket

via: SeekingAlpha at 2018-10-12 06:18:33:000

AmpliPhi Biosciences (NYSEMKT: APHB ) prices its public offering of 16,537,500 shares of common stock and warrants to purchase up to 16,537,500 common shares and pre-funded warrants at a combined price of $0.40. More news on: AmpliPhi Biosciences Corp., Healthcare stocks news, Stocks on … read more...

AmpliPhi Biosciences prices $6.6M equity offering; shares down 34% premarket

via: SeekingAlpha at 2018-10-12 06:18:33:000

AmpliPhi Biosciences (NYSEMKT: APHB ) prices its public offering of 16,537,500 shares of common stock and warrants to purchase up to 16,537,500 common shares and pre-funded warrants at a combined price of $0.40. More news on: AmpliPhi Biosciences Corp., Healthcare stocks news, Stocks on … read more...

AmpliPhi Biosciences prices $6.6M equity offering; shares down 34% premarket

via: SeekingAlpha at 2018-10-12 06:18:33:000

AmpliPhi Biosciences (NYSEMKT: APHB ) prices its public offering of 16,537,500 shares of common stock and warrants to purchase up to 16,537,500 common shares and pre-funded warrants at a combined price of $0.40. More news on: AmpliPhi Biosciences Corp., Healthcare stocks news, Stocks on … read more...

AmpliPhi Biosciences Announces Pricing of $6.6 Million Underwritten Public Offering

via: Business Wire at 2018-10-12 06:00:00:000

AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the pricing of an underwritten pub… read more...

AmpliPhi Biosciences Announces Pricing of $6.6 Million Underwritten Public Offering

via: Business Wire at 2018-10-12 06:00:00:000

AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the pricing of an underwritten pub… read more...

AmpliPhi Biosciences Announces Pricing of $6.6 Million Underwritten Public Offering

via: Business Wire at 2018-10-12 06:00:00:000

AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the pricing of an underwritten pub… read more...

AmpliPhi Biosciences Announces Pricing of $6.6 Million Underwritten Public Offering

via: Business Wire at 2018-10-12 06:00:00:000

AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the pricing of an underwritten pub… read more...

AmpliPhi Biosciences Announces Presentation of Positive Clinical Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference

via: Business Wire at 2018-10-08 06:50:00:000

13 patients with serious and life-threatening S. aureus infections were treated with AB-SA01 at the Westmead Hospital in Sydney under AmpliPhis expanded access program Patients suffered from severe S. aureus bacteremia and sepsis, including infective endocarditis and prosthe… read more...

AmpliPhi Biosciences Announces Presentation of Positive Clinical Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference

via: Business Wire at 2018-10-08 06:50:00:000

13 patients with serious and life-threatening S. aureus infections were treated with AB-SA01 at the Westmead Hospital in Sydney under AmpliPhis expanded access program Patients suffered from severe S. aureus bacteremia and sepsis, including infective endocarditis and prosthe… read more...

AmpliPhi Biosciences Announces Presentation of Positive Clinical Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference

via: Business Wire at 2018-10-08 06:50:00:000

13 patients with serious and life-threatening S. aureus infections were treated with AB-SA01 at the Westmead Hospital in Sydney under AmpliPhis expanded access program Patients suffered from severe S. aureus bacteremia and sepsis, including infective endocarditis and prosthe… read more...

AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018

via: Business Wire at 2018-09-24 06:50:00:000

Professor Jonathan Iredell to present data from AmpliPhi Biosciences ongoing expanded access program for bacteriophage product candidates AB-SA01 (targeting S. aureus) and AB-PA01 (targeting P. aeruginosa) AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clini… read more...

AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018

via: Business Wire at 2018-09-24 06:50:00:000

Professor Jonathan Iredell to present data from AmpliPhi Biosciences ongoing expanded access program for bacteriophage product candidates AB-SA01 (targeting S. aureus) and AB-PA01 (targeting P. aeruginosa) AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clini… read more...

AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018

via: Business Wire at 2018-09-24 06:50:00:000

Professor Jonathan Iredell to present data from AmpliPhi Biosciences ongoing expanded access program for bacteriophage product candidates AB-SA01 (targeting S. aureus) and AB-PA01 (targeting P. aeruginosa) AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clini… read more...

AmpliPhi Bio on go with two studies supporting AB-PA01; shares up 2% premarket

via: SeekingAlpha at 2018-09-18 09:12:01:000

Thinly traded nano cap AmpliPhi Biosciences (NYSEMKT: APHB ) is up 2% premarket on increased volume in response to its announcement that that the FDA has signed off on its development plan for bacteriophage therapeutic AB-PA01 . More news on: AmpliPhi Biosciences Corp., He… read more...

AmpliPhi Bio on go with two studies supporting AB-PA01; shares up 2% premarket

via: SeekingAlpha at 2018-09-18 09:12:01:000

Thinly traded nano cap AmpliPhi Biosciences (NYSEMKT: APHB ) is up 2% premarket on increased volume in response to its announcement that that the FDA has signed off on its development plan for bacteriophage therapeutic AB-PA01 . More news on: AmpliPhi Biosciences Corp., He… read more...

AmpliPhi Bio on go with two studies supporting AB-PA01; shares up 2% premarket

via: SeekingAlpha at 2018-09-18 09:12:01:000

Thinly traded nano cap AmpliPhi Biosciences (NYSEMKT: APHB ) is up 2% premarket on increased volume in response to its announcement that that the FDA has signed off on its development plan for bacteriophage therapeutic AB-PA01 . More news on: AmpliPhi Biosciences Corp., He… read more...

AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-PA01 Targeting Pseudomonas Aeruginosa Infections

via: Business Wire at 2018-09-18 08:00:00:000

The FDA is in general agreement with the design of two proposed randomized clinical trials of AB-PA01, hospital-acquired and ventilator-associated pneumonia (HAP/VAP) due to P. aeruginosa and for P. aeruginosa bacteremia, and no additional preclinical or clinical data are required to proc… read more...

AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-PA01 Targeting Pseudomonas Aeruginosa Infections

via: Business Wire at 2018-09-18 08:00:00:000

The FDA is in general agreement with the design of two proposed randomized clinical trials of AB-PA01, hospital-acquired and ventilator-associated pneumonia (HAP/VAP) due to P. aeruginosa and for P. aeruginosa bacteremia, and no additional preclinical or clinical data are required to proc… read more...

AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-PA01 Targeting Pseudomonas Aeruginosa Infections

via: Business Wire at 2018-09-18 08:00:00:000

The FDA is in general agreement with the design of two proposed randomized clinical trials of AB-PA01, hospital-acquired and ventilator-associated pneumonia (HAP/VAP) due to P. aeruginosa and for P. aeruginosa bacteremia, and no additional preclinical or clinical data are required to proc… read more...

AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-SA01

via: Business Wire at 2018-09-17 09:00:00:000

FDA is in general agreement with the design of two proposed randomized clinical trials of AB-SA01, for Staphylococcus aureus bacteremia and prosthetic joint infections, and no additional preclinical or clinical data are required to proceed with both trials AmpliPhi expects to initia… read more...

AmpliPhi Biosciences Announces Updated Positive Clinical Results for its Expanded Access Program

via: Business Wire at 2018-09-17 08:00:00:000

21 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have now been treated with AB-SA01 (targeting S. aureus) or AB-PA01 (targeting P. aeruginosa) under AmpliPhis expanded access program Over 1,000 doses of bacteriophage prod… read more...

Midday Gainers / Losers (08/22/2018)

via: SeekingAlpha at 2018-08-22 12:45:18:000

Gainers: YECO +56% . NEWA +30% . EXAS +26% . MYND +22% . PSTG +17% . AGEN +14% . LZB +12% . ADMP +12% . MYGN +11% . EPE +11% . More news on: Yulong Eco-Materials, Newater Technology, Inc., EXACT Sciences Corporation, Stocks on the move, , Read more … ... read more...

Midday Gainers / Losers (08/22/2018)

via: SeekingAlpha at 2018-08-22 12:45:18:000

Gainers: YECO +56% . NEWA +30% . EXAS +26% . MYND +22% . PSTG +17% . AGEN +14% . LZB +12% . ADMP +12% . MYGN +11% . EPE +11% . More news on: Yulong Eco-Materials, Newater Technology, Inc., EXACT Sciences Corporation, Stocks on the move, , Read more … ... read more...

Midday Gainers / Losers (08/22/2018)

via: SeekingAlpha at 2018-08-22 12:45:18:000

Gainers: YECO +56% . NEWA +30% . EXAS +26% . MYND +22% . PSTG +17% . AGEN +14% . LZB +12% . ADMP +12% . MYGN +11% . EPE +11% . More news on: Yulong Eco-Materials, Newater Technology, Inc., EXACT Sciences Corporation, Stocks on the move, , Read more … ... read more...

AmpliPhi Biosciences Reports Second Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-08-09 06:50:00:000

19 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have been treated with AB-SA01 or AB-PA01 under single-patient expanded access program AmpliPhi has scheduled meetings with the FDA in August and September to discuss the regulator… read more...

AmpliPhi Biosciences Reports Second Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-08-09 06:50:00:000

19 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have been treated with AB-SA01 or AB-PA01 under single-patient expanded access program AmpliPhi has scheduled meetings with the FDA in August and September to discuss the regulator… read more...

AmpliPhi Biosciences Reports Second Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-08-09 06:50:00:000

19 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have been treated with AB-SA01 or AB-PA01 under single-patient expanded access program AmpliPhi has scheduled meetings with the FDA in August and September to discuss the regulator… read more...

AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Studies at American Society of Microbiology Annual Meeting

via: Business Wire at 2018-06-07 16:15:00:000

AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a late-breaker poster presentation describing four case studies of patients suffering… read more...

AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Studies at American Society of Microbiology Annual Meeting

via: Business Wire at 2018-06-07 16:15:00:000

AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a late-breaker poster presentation describing four case studies of patients suffering… read more...

AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Studies at American Society of Microbiology Annual Meeting

via: Business Wire at 2018-06-07 16:15:00:000

AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a late-breaker poster presentation describing four case studies of patients suffering… read more...

AmpliPhi Biosciences Announces Presentation of AB-PA01 Bacteriophage Therapy Case Study at 41st European Cystic Fibrosis Conference

via: Business Wire at 2018-06-07 08:00:00:000

AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a poster presentation of a successful case study of a patient with cystic fibrosis, s… read more...

AmpliPhi Biosciences Announces Presentation of AB-PA01 Bacteriophage Therapy Case Study at 41st European Cystic Fibrosis Conference

via: Business Wire at 2018-06-07 08:00:00:000

AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a poster presentation of a successful case study of a patient with cystic fibrosis, s… read more...

AmpliPhi Biosciences Announces Presentation of AB-PA01 Bacteriophage Therapy Case Study at 41st European Cystic Fibrosis Conference

via: Business Wire at 2018-06-07 08:00:00:000

AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a poster presentation of a successful case study of a patient with cystic fibrosis, s… read more...

Reader Inquiry: Is A Run-Up In The Cards For AmpliPhi BioSciences?

via: SeekingAlpha at 2018-05-20 21:19:32:000

Shares of AmpliPhi Biosciences (APHB) have lost nearly three quarters of their value since the beginning of 2017, with investors sucked in by the exciting story of their bacteriophage therapies taking quite the beating. Year to date, the stock has risen by 15% (at one point over 50% in March)…. read more...

AmpliPhi Biosciences to Present at 5th World Congress on Targeting Infectious Diseases: Targeting Phage & Antibiotic Resistance 2018

via: Business Wire at 2018-05-18 06:50:00:000

AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced its participation in the 5 th World Congress on Targeting Infectious Diseases &#x201… read more...

Ampliphi Biosciences Corp. 2018 Q1 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-05-16 14:19:48:000

The following slide deck was published by Ampliphi Biosciences Corp. in conjunction with their 2018 Q1 earnings Read more … read more...

Ampliphi Biosciences Corp. 2018 Q1 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-05-16 14:19:48:000

The following slide deck was published by Ampliphi Biosciences Corp. in conjunction with their 2018 Q1 earnings Read more … read more...

AmpliPhi Biosciences' (APHB) CEO Paul Grint on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-15 20:38:08:000

AmpliPhi Biosciences Corporation (APHB) Q1 2018 Results Earnings Conference Call May 15, 2018 04:30 PM ET Executives Matt Dansey - Manager, Business Development Paul Grint - CEO Igor Bilinsky - COO Steve Martin - CFO Analysts Joe Pantginis - HC Wainwright David Bautz - … read more...

AmpliPhi Biosciences' (APHB) CEO Paul Grint on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-15 20:38:08:000

AmpliPhi Biosciences Corporation (APHB) Q1 2018 Results Earnings Conference Call May 15, 2018 04:30 PM ET Executives Matt Dansey - Manager, Business Development Paul Grint - CEO Igor Bilinsky - COO Steve Martin - CFO Analysts Joe Pantginis - HC Wainwright David Bautz - … read more...

AmpliPhi Biosciences' (APHB) CEO Paul Grint on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-15 20:38:08:000

AmpliPhi Biosciences Corporation (APHB) Q1 2018 Results Earnings Conference Call May 15, 2018 04:30 PM ET Executives Matt Dansey - Manager, Business Development Paul Grint - CEO Igor Bilinsky - COO Steve Martin - CFO Analysts Joe Pantginis - HC Wainwright David Bautz - … read more...

AmpliPhi Biosciences' (APHB) CEO Paul Grint on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-15 20:38:08:000

AmpliPhi Biosciences Corporation (APHB) Q1 2018 Results Earnings Conference Call May 15, 2018 04:30 PM ET Executives Matt Dansey - Manager, Business Development Paul Grint - CEO Igor Bilinsky - COO Steve Martin - CFO Analysts Joe Pantginis - HC Wainwright David Bautz - … read more...

AmpliPhi Biosciences misses by $0.05

via: SeekingAlpha at 2018-05-15 16:08:58:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q1 EPS of -$0.24 misses by $0.05 . More news on: Ampliphi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences misses by $0.05

via: SeekingAlpha at 2018-05-15 16:08:58:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q1 EPS of -$0.24 misses by $0.05 . More news on: Ampliphi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences misses by $0.05

via: SeekingAlpha at 2018-05-15 16:08:58:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q1 EPS of -$0.24 misses by $0.05 . More news on: Ampliphi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences misses by $0.05

via: SeekingAlpha at 2018-05-15 16:08:58:000

AmpliPhi Biosciences (NYSEMKT: APHB ): Q1 EPS of -$0.24 misses by $0.05 . More news on: Ampliphi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences Reports First Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-05-15 16:02:00:000

Announced positive topline results for the initial seven patients treated with AB-SA01 or AB-PA01 under ongoing expanded access program and presented detailed results for the first patient at a medical conference Signed collaborative agreements with the U.S. Department of Veterans A… read more...

AmpliPhi Biosciences Reports First Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-05-15 16:02:00:000

Announced positive topline results for the initial seven patients treated with AB-SA01 or AB-PA01 under ongoing expanded access program and presented detailed results for the first patient at a medical conference Signed collaborative agreements with the U.S. Department of Veterans A… read more...

AmpliPhi Biosciences Reports First Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-05-15 16:02:00:000

Announced positive topline results for the initial seven patients treated with AB-SA01 or AB-PA01 under ongoing expanded access program and presented detailed results for the first patient at a medical conference Signed collaborative agreements with the U.S. Department of Veterans A… read more...

AmpliPhi Biosciences Reports First Quarter 2018 Financial Results and Business Highlights

via: Business Wire at 2018-05-15 16:02:00:000

Announced positive topline results for the initial seven patients treated with AB-SA01 or AB-PA01 under ongoing expanded access program and presented detailed results for the first patient at a medical conference Signed collaborative agreements with the U.S. Department of Veterans A… read more...

AmpliPhi Biosciences to Hold 2018 First Quarter and Business Update Conference Call on May 15

via: Business Wire at 2018-05-08 06:50:00:000

AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that management will hold a business update conference call on Tuesday,… read more...

AmpliPhi Biosciences to Hold 2018 First Quarter and Business Update Conference Call on May 15

via: Business Wire at 2018-05-08 06:50:00:000

AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that management will hold a business update conference call on Tuesday,… read more...

AmpliPhi Biosciences Will Utilize NIAID Preclinical Services to Advance Development of Its Targeted Therapeutic Candidate for the Treatment of Resistant Staphylococcus Aureus

via: Business Wire at 2018-05-03 16:15:00:000

AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it will utilize the Therapeutic Development Services funded by the National Inst… read more...

AmpliPhi Biosciences Will Utilize NIAID Preclinical Services to Advance Development of Its Targeted Therapeutic Candidate for the Treatment of Resistant Staphylococcus Aureus

via: Business Wire at 2018-05-03 16:15:00:000

AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it will utilize the Therapeutic Development Services funded by the National Inst… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-04-06 07:14:53:000

Noteworthy events during the week of April 8 - 14 for healthcare investors. More news on: Avita Medical Ltd., Immunovaccine Inc., Intercept Pharmaceuticals, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-04-06 07:14:53:000

Noteworthy events during the week of April 8 - 14 for healthcare investors. More news on: Avita Medical Ltd., Immunovaccine Inc., Intercept Pharmaceuticals, Healthcare stocks news, , Read more … read more...

AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Study at ISHLT Annual Meeting

via: Business Wire at 2018-04-03 06:50:00:000

AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the presentation of a case study of a lung transplant recipient suffering from a resi… read more...

AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Study at ISHLT Annual Meeting

via: Business Wire at 2018-04-03 06:50:00:000

AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the presentation of a case study of a lung transplant recipient suffering from a resi… read more...

AmpliPhi Biosciences Announces Closing of Registered Direct Offering of Common Stock

via: Business Wire at 2018-03-22 16:10:00:000

AmpliPhi Biosciences Corporation (NYSE American: APHB) , a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced the closing of its previously announced registered direct offering of 2,743,640 shares of its common… read more...

Midday Gainers / Losers (03/20/2018)

via: SeekingAlpha at 2018-03-20 12:45:20:000

ARNA +33% . CRME +24% . MULE +21% . SRI +19% . ACMR +15% . MDWD +16% . CASI +15% . MRNS +14% . PAR +14% . VSLR +13% . HQY +12% . More news on: Arena Pharmaceuticals, Inc., Cardiome Pharma Corporation, MuleSoft, , Stocks on the move, Read more … read more...

Premarket Losers as of 9:05 am (3/20/2018)

via: SeekingAlpha at 2018-03-20 09:11:17:000

APHB -17% on commencing direct stock offering at $1.10.. More news on: Ampliphi Biosciences Corp., NF Energy Saving Corp., Northern Oil & Gas, Inc, Stocks on the move, , Read more … read more...

Midday Gainers / Losers

via: SeekingAlpha at 2018-01-10 12:38:16:000

Gainers: LEDS +81% . KODK +59% . NVAX +40% . BMRA +34% . TSRI +31% . AFSI +27% . TNDM +26% . DPW +25% . PAVM +24% . HMNY +21% . More news on: SemiLEDs Corporation, Eastman Kodak Co., Novavax, Inc., Stocks on the move, Read more … read more...

Premarket Losers as of 9:05 am

via: SeekingAlpha at 2018-01-10 09:11:06:000

APHB -33% on pricing stock offering at $1.00. More news on: Ampliphi Biosciences Corp., Klondex Mines Ltd., Spherix Incorporated, Stocks on the move, Read more … read more...

AmpliPhi Bio prices stock offering at $1.00; shares down 28% premarket

via: SeekingAlpha at 2018-01-10 07:03:14:000

Nano cap AmpliPhi Biosciences (NYSEMKT: APHB ) slumps 28% premarket on light volume in response to its public offering of 4M shares of common stock at $1.00 per share. Closing date is January 12. More news on: Ampliphi Biosciences Corp., Healthcare stocks news, Stocks on the … read more...

AmpliPhi Biosciences Announces Pricing of $4.0 Million Public Offering of Common Stock

via: Business Wire at 2018-01-10 06:00:00:000

AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the pricing of a public offering of 4,000,000 shares of its common stock, offered at … read more...

AmpliPhi Biosciences Announces Proposed Public Offering of Common Stock

via: Business Wire at 2018-01-09 17:13:00:000

AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it intends to offer shares of its common stock in a public offering. H.C. Wa… read more...

Midday Gainers / Losers

via: SeekingAlpha at 2018-01-09 12:42:09:000

Gainers: PTIE +143% . DFFN +39% . KODK +31% . KEN +27% . CGG +24% . ITUS +21% . ALDR +20% . MMAC +19% . GBT +18% . ABAX +17% . More news on: Pain Therapeutics, Diffusion Pharmaceuticals Inc., Eastman Kodak Co., Stocks on the move, Read more … read more...

Midday Gainers / Losers

via: SeekingAlpha at 2018-01-08 12:59:55:000

Gainers: MYSZ +70% . DELT +29% . APHB +22% . GALT +18% . SIFY +17% . AMSC +17% . LPCN +17% . VUZI +17% . NVRO +16% . CBMG +16% . More news on: MySize Inc., Delta Technology Holdings Limited, Ampliphi Biosciences Corp., Stocks on the move, Read more … ... read more...

Midday Gainers / Losers

via: SeekingAlpha at 2018-01-04 12:40:33:000

Gainers: CNET +315% . APOP +48% . HTGM +42% . AEMD +42% . CCXI +34% . OMF +24% . CMCM +20% . CCCR +18% . TCCO +17% . APHB +17% . More news on: ChinaNet Online Holdings, Inc., Cellect Biotechnology Ltd., HTG Molecular Diagnostics, Stocks on the move, Rea… read more...

Biotech Forum Daily Digest: A Volatile Opening To 2018

via: SeekingAlpha at 2018-01-04 11:33:07:000

I am fond of pigs. Dogs look up to us. Cats look down on us. Pigs treat us as equals . Winston S. Churchill The biotech sector opened with a bang here in 2018. Solid rallies Tuesday and Wednesday were followed by a quick reversal this morning. After opening up, it seemed … read more...

AmpliPhi Biosciences (APHB) Updates On Interim Results of Expanded Access Program of AB-SA01 & AB-PA01 - Slideshow

via: SeekingAlpha at 2018-01-04 11:10:01:000

The following slide deck was published by Ampliphi Biosciences Corp. in conjunction with this Read more … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2017-04-25 10.0 1.0 10.0
2015-08-07 50.0 1.0 50.0
Data provided for free by IEX